CN Patent

CN100475819C — 一种拟多晶型hiv蛋白酶抑制剂

Assigned to Janssen R&D Ireland ULC · Expires 2009-04-08 · 17y expired

What this patent protects

本发明公开(3R，3aS，6aR)-六氢呋喃并[2，3-b]呋喃-3-基(1S，2R)-3-[[(4-氨基苯基)磺酰基](异丁基)氨基]-1-苄基-2-羟基丙基氨基甲酸酯的新颖的多晶型物及其生产方法。

USPTO Abstract

本发明公开(3R，3aS，6aR)-六氢呋喃并[2，3-b]呋喃-3-基(1S，2R)-3-[[(4-氨基苯基)磺酰基](异丁基)氨基]-1-苄基-2-羟基丙基氨基甲酸酯的新颖的多晶型物及其生产方法。

Drugs covered by this patent

Prezista (DARUNAVIR) · Janssen Prods

Patent Metadata

Patent number: CN100475819C
Jurisdiction: CN
Classification: —
Expires: 2009-04-08
Drug substance claim: No
Drug product claim: No
Assignee: Janssen R&D Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.